Code
NTG-AMLX-02CX
Test
Active-Compendium
81450x1
81450
Clinical
Oncology,Pathology
<p><b>Bone Marrow Aspirate:</b> 2 mL in EDTA tube. Sodium heparin is acceptable.<br> <b>Peripheral Blood:</b> 5 mL in EDTA tube. Sodium heparin is acceptable.<br> <b>H&E slide:</b> Required, plus paraffin block.<br> <b>Cut Slides:</b> H&E slide (required) plus 10-14 unstained slides cut at 5+ microns.<br> <b>Note on FFPE:</b> Paraffin block is preferred. Do not use zinc fixatives. If submitting slides, please use positively-charged slides and 10% NBF fixative. Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.<br> <b>Do not use:</b> Mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.<br> <b>Note:</b> Test is TNA-based. Please select Extract & Hold - TNA if specimen hold service is desired.</p>
Flag Active
True
Orderable Test Description
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Molecular profiling with the NeoTYPE AML Prognostic Profile is appropriate for AML patients with intermediate-risk cytogenetic abnormalities, which is a heterogeneous group. This panel is designed to detect key genetic alterations associated with acute myeloid leukemia (AML) through next-generation sequencing (NGS). It includes the following genes:</p>
<p><br>DNA NGS (SNV/Indel):<br>ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2, KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PML, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2<br><br>Test Customization: FLT3 by PCR (via FLT3 Mutation Analysis) is available for concurrent testing as a Client-Bill option. It is reported separately to support prompt therapy selection in newly diagnosed AML cases.<br><br>Test Recommendations: For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, the NeoTYPE® MDS/CMML Profile is recommended.</p>
<p><br>DNA NGS (SNV/Indel):<br>ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2, KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PML, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2<br><br>Test Customization: FLT3 by PCR (via FLT3 Mutation Analysis) is available for concurrent testing as a Client-Bill option. It is reported separately to support prompt therapy selection in newly diagnosed AML cases.<br><br>Test Recommendations: For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, the NeoTYPE® MDS/CMML Profile is recommended.</p>
Orderable Turn Around Time
14 Days
Orderable Biomarkers
NY Approved
True
Orderable Biomarkers JSON
{"DNA Sequencing": {"SNVs + Indels": ["CSF3R", "DNMT3A", "ETV6", "EZH2", "HRAS", "IDH1", "IDH2", "KIT", "KMT2A", "KRAS", "NPM1", "NRAS", "PHF6", "PML", "PTPN11", "RUNX1", "SETBP1", "SF3B1", "SRSF2", "STAG2", "TET2", "U2AF1", "WT1", "ZRSR2", "FLT3", "JAK2", "PDGFRA", "TP53", "ASXL1", "BCOR", "BRAF", "CEBPA"]}}
Keywords string
precision profile, solid tumors, neo type, NeoTYPE Precision Profile for Solid Tumors. NeoTYPE® AML Prognostic Profile
Title URL
neotype-aml-prognostic-profile
Clinical Significance
Molecular profiling with the NeoTYPE AML Prognostic Profile is appropriate for AML patients with intermediate-risk cytogenetic abnormalities, which is a heterogeneous group. This Profile can refine and improve risk stratification by confirming intermediate risk or reclassifying patients to more favorable or unfavorable risk categories. This change in risk classification may have therapeutic implications. For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoTYPE MDS/CMML Profile.
Storage and transportation
Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of collection. Please select Extract & Hold - TNA if specimen hold service is desired.